5 citations
,
May 2023 in “Microbial Cell Factories” A stable, active version of a growth factor was made in bacteria, showing promise for medical use.
2 citations
,
August 2017 in “Experimental Dermatology” A human serum-enriched medium effectively supports melanocyte growth and activity without using animal-derived supplements.
41 citations
,
July 2016 in “Journal of Investigative Dermatology” Dysplastic nevi have unique gene expressions, making them distinct from common melanocytic nevi.
8 citations
,
March 2012 in “Mass spectrometry letters” The S9 fraction with GC-IDMS is effective for measuring 5α-reductase activity.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
January 2023 in “Pediatrics International” Non-classical 21-hydroxylase deficiency can be missed in newborn screenings and should be considered in cases of early puberty or virilization.
January 2016 in “Huanjing yu Jiankang Zazhi” 20 citations
,
December 1999 in “Journal of Investigative Dermatology” Mutations in the hHb6 gene cause the hair disorder monilethrix.
22 citations
,
October 2001 in “Biochemical Pharmacology” GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
January 2026 in “Frontiers in Molecular Biosciences” A new method helps diagnose alopecia areata using specific gene markers and could guide targeted treatments.
February 2026 in “Journal of Dermatological Treatment” CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.
2 citations
,
April 2008 in “PubMed” A gene mutation causes monilethrix in a Chinese family.
The trichohyalin gene is located at chromosomal region 1q21 with other skin-related protein genes.
December 2024 in “African Journal of Biomedical Research” Combining dexmedetomidine and ketamine provides better sedation and pain relief than dexmedetomidine alone.
63 citations
,
May 2015 in “PloS one” GALT5 and GALT2 are important for plant growth and development because they help with protein glycosylation.
7 citations
,
June 2017 in “Gene” Overexpression of FGF5s makes Chinese Merino sheep grow longer and heavier wool.
9 citations
,
March 2017 in “Journal of Visualized Experiments” The assay effectively identifies compounds that affect immune cell activation.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
30 citations
,
December 1996 in “Journal of Investigative Dermatology”
8 citations
,
June 1995 in “Helvetica Chimica Acta” Compound 15a was effective in inhibiting 5α-reductase.
September 2024 in “Journal of the Pakistan Medical Association” A 589 nm laser increases IL-2 and IFN-y gene expression in human T-cells.
6 citations
,
February 2009 in “Journal of Investigative Dermatology”
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” A patient with a new PLEC gene mutation showed symptoms of both muscular dystrophy and myasthenia gravis, which improved with steroid treatment.
June 2025 in “JCEM Case Reports” False high testosterone levels were corrected using a more accurate test.
January 2026 in “Open Science Framework” Biochanin A from soy is a promising and safe candidate for treating hair loss.
January 2026 in “Journal of Materials Chemistry B” A special solvent helps hydroxytyrosol penetrate skin better, promoting hair growth.
September 2024 in “Journal of the American Academy of Dermatology” The compounded topical solution is safe, stable, and effective for personalized alopecia treatment.
26 citations
,
October 1998 in “Experimental Dermatology” A keratin hHb6 mutation causes a hair disorder with varying severity, influenced by other factors.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.